GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different
ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by
blocking blood flow to the tumor. Giving GM-CSF and thalidomide before surgery may make the
tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving GM-CSF together with thalidomide
works in treating patients undergoing surgery for high-risk prostate cancer.